Omnicare : Omnicare : Omnicare Specialty Care Group Expands Pharmacy and Brand Support Services for DIFICID® (fidaxomicin) tablets ORLANDO, February 4, 2013 - Omnicare Specialty Care Group (SCG) has expanded its service offering for Optimer's DIFICID^® (fidaxomicin) tablets to include brand support in addition to specialty pharmacy dispensing services. DIFICID is a macrolide antibacterial drug indicated in adults 18 years of age and older for the treatmentof Clostridium difficile-associated diarrhea. Omnicare SCG's specialty pharmacy, Advanced Care Scripts (ACS) supports Optimer's DIFICID Rx Assist(TM) program, which facilitates a continuum of care for patients as they transition from the hospital to the home or other setting. In managing DIFICID Rx Assist, ACS supports an access and reimbursement hotline and the application process for the Optimer Patient Assistance Program. The new model also includes support for the DIFICID Co-Pay Assistance Program, which provides up to $200 toward a commercially insured patient's copayment obligation for 1 DIFICID prescription up to 20 tablets per calendar year. "We are excited to be working with Optimer in this expanded capacity," said David Hileman, Senior Vice President of Omnicare Specialty Care Group."The DIFICID Rx Assist Program will help address potential issues and challenges encountered in today's marketplace, including education and access to therapy. Each aspect of the program is designed to help facilitate the continuum of care for patients." ACS manages and dispenses specialty medications in multiple disease categories, including cancer, infectious diseases, auto-immune disorders, multiple sclerosis and hemophilia. Its expertise across both the specialty and long-term care channels allows it to provide comprehensive solutions for prescribers and patients. About Omnicare Specialty Care Group Omnicare Specialty Care Group (SCG) is a division of Omnicare, Inc., a Fortune 400 company and provider of comprehensive pharmaceutical services based in Cincinnati, Ohio. Omnicare SCG is a combination of synergistic tenured companies with a focused approach to pharmaceutical brand solutions. Together, Omnicare SCG brings specialists in reimbursement methods, clinicians practiced in medication therapy management for chronic disease states, and distribution channel expertise. Solutions are tailored to drive product access by solving challenges faced by patients and their caregivers, physicians, payers and manufacturers. Custom programs are led by a single management team across the organizational platforms, allowing coordination of resources and assets to support positive outcomes for our patients. For more information, visit www.omnicarescg.com About Omnicare Omnicare, Inc., a Fortune 400 company based in Cincinnati, Ohio, provides comprehensive pharmaceutical services to patients and providers across North America. As the market-leader in professional pharmacy, related consulting and data management services for skilled nursing, assisted living and other chronic care institutions, Omnicare leverages its unparalleled clinical insight into the geriatric market along with some of the industry's most innovative technological capabilities to the benefit of its long-term care customers. Omnicare also provides key commercialization services for the bio-pharmaceutical industry and end-of-life disease management through its Specialty Care Group. For more information, visit http://www.omnicare.com/. Important Safety Information DIFICID is contraindicated in patients with hypersensitivity to fidaxomicin or to any of the excipients in the formulation. DIFICID should not be used for systemic infections. Only use DIFICID for infection proven or strongly suspected to be caused by C. difficile. Prescribing DIFICID in the absence of a proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%) and neutropenia (2%) # # # Contact: Media: Ed Loyd (513) 719-0808 email@example.com Business: David Hileman (502) 213-1104 firstname.lastname@example.org ------------------------------------------------------------------------------ This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Omnicare via Thomson Reuters ONE HUG#1675140
Omnicare : Omnicare : Omnicare Specialty Care Group Expands Pharmacy and Brand Support Services for DIFICID® (fidaxomicin)
Press spacebar to pause and continue. Press esc to stop.